再燃前立腺癌に対するVincristine,Ifosfamide,Peplomycin併用療法(VIP療法)

Abstract

再燃stage D前立腺癌患者10例に対し, VIP療法を施行した.1)疼痛では50%の例に改善をみたが, 他覚所見に対する有効率は低かった.2)総合効果では, Karnofskyの基準で20%, 志田らの基準で10%, NPCPの基準で50%, 小山・斎藤班の基準で10%の有効率であった.3)副作用は, 肝不全となり死亡した1例を除いては, 消化器症状, 脱毛, 発熱など, 比較的軽度であった

Ten patients with reactivated stage D prostatic cancer were treated with the combination therapy of vincristine, ifosfamide and peplomycin (VIP therapy). This treatment gave a good relief of bone pain in 4 out of 8 patients (50%) and improvement of dysuria in 2 out of 6 patients (33%), but objective responses of primary and metastatic lesions were poor. The over-all response rate was 20% by Karnofsky's category of response, 10% by the response criteria of Shida et al., 50% by National Prostatic Cancer Project criteria in the United States and 10% by the response criteria of Koyama and Saito's group. The toxicity of VIP therapy was mild to moderate except for hepatic insufficiency shown in one case.